MX2023007347A - Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. - Google Patents

Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.

Info

Publication number
MX2023007347A
MX2023007347A MX2023007347A MX2023007347A MX2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A MX 2023007347 A MX2023007347 A MX 2023007347A
Authority
MX
Mexico
Prior art keywords
alcoholic steatohepatitis
oxygen
treatment
fatty acids
combination therapies
Prior art date
Application number
MX2023007347A
Other languages
English (en)
Inventor
David Alan Fraser
Original Assignee
Northsea Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northsea Therapeutics B V filed Critical Northsea Therapeutics B V
Publication of MX2023007347A publication Critical patent/MX2023007347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona una terapia de combinación para usarse en el tratamiento terapéutico y/o profiláctico de la esteatohepatitis no alcohólica (NASH) y/o la esteatohepatitis alcohólica (ASH), en donde la terapia de combinación comprende un ácido graso insaturado con oxígeno incorporado en la posición ß y un sustituyente a y al menos un agente activo adicional elegido de un agonista del receptor del péptido 1 similar al glucagón, un inhibidor de acetil-CoA carboxilasa y un agonista del receptor farnesoide X.
MX2023007347A 2020-12-22 2021-12-21 Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. MX2023007347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128996P 2020-12-22 2020-12-22
PCT/IB2021/062115 WO2022137125A1 (en) 2020-12-22 2021-12-21 Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
MX2023007347A true MX2023007347A (es) 2023-08-16

Family

ID=79283090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007347A MX2023007347A (es) 2020-12-22 2021-12-21 Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.

Country Status (8)

Country Link
EP (1) EP4267124A1 (es)
JP (1) JP2023554524A (es)
KR (1) KR20230128307A (es)
CN (1) CN116829139A (es)
AU (1) AU2021405273A1 (es)
CA (1) CA3201254A1 (es)
MX (1) MX2023007347A (es)
WO (1) WO2022137125A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733353T3 (es) 2007-11-09 2019-11-28 Basf As Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento
CA2760877C (en) 2009-05-08 2020-09-08 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
EP2526084A1 (en) 2010-01-20 2012-11-28 Pronova BioPharma Norge AS Salicylate fatty acid derivatives
ES2618604T3 (es) * 2010-11-05 2017-06-21 Pronova Biopharma Norge As Métodos de tratamiento usando compuestos lipídicos
WO2014132134A1 (en) * 2013-02-28 2014-09-04 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
DK2961727T3 (en) 2013-02-28 2017-03-13 Pronova Biopharma Norge As Process for Preparation of 2 - ((5Z, 8Z, 11Z, 14Z, 17Z) -icosa-5,8,11,14,17-pentaenyloxy) -butanoic acid
AU2015389862B2 (en) 2015-04-01 2021-04-15 Pronova Biopharma Norge As Use of thia oxo compounds for lowering Apo C3
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049173A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20190142905A1 (en) * 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
JP7175897B2 (ja) * 2016-12-28 2022-11-21 モデュネクス・バイオ・コーポレーション 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法
CA3058542A1 (en) * 2017-04-18 2018-10-25 Genfit Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
CN113056266A (zh) * 2018-09-18 2021-06-29 梅塔科林公司 用于治疗疾病的法尼醇x受体激动剂

Also Published As

Publication number Publication date
EP4267124A1 (en) 2023-11-01
CA3201254A1 (en) 2022-06-30
WO2022137125A1 (en) 2022-06-30
KR20230128307A (ko) 2023-09-04
AU2021405273A1 (en) 2023-08-10
CN116829139A (zh) 2023-09-29
JP2023554524A (ja) 2023-12-27

Similar Documents

Publication Publication Date Title
MX2020005621A (es) Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
MY117830A (en) Therapeutic combinations of fatty acids
HK1060302A1 (en) Methods of therapy with thrombin derived peptides
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
WO2010030180A3 (en) Peptide formulations and uses thereof
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
HK1051001A1 (en) Use of relaxin to treat diseases related to vasoconstriction
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
MXPA03001798A (es) Composiciones y metodos para tratar trastorno sexual.
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
FR2863169B1 (fr) Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
SI1677806T1 (sl) Postopki za zdravljenje akutnega in s preobremenitvijo povzročenega zvina in natega z uporabo hialuronske kisline
MX2023007347A (es) Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica.
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
MX2021005801A (es) Metodos para administrar corticosteroides.
IS7912A (is) Notkun dókósahexensýru sem virks efnis til að meðhöndla fitukyrking
BR0307022A (pt) Método de tratamento de um paciente que precisa de analgesia
Bhatia et al. Human pharmacokinetics and safety of subcutaneous collagenase Clostridium histolyticum in women
UA97961C2 (ru) Способ лечения и/или улучшения диссеминированного внутрисосудистого свертывания крови
PE20020362A1 (es) Inhibidores de aminotransferasa que dependen del amino acido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas
MX2022015760A (es) Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.